Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael ...
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein (HSIC – Research Report) on November 5 and set a price ...
Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.
Zacks.com on MSN13d
HSIC Q3 Earnings Top, Margins Down, Stock Gains in PremarketHSIC registered adjusted earnings per share (EPS) of $1.22 in the third quarter of 2024, down 7.6% from the year-ago figure.
The global periodontal disease treatment market is projected to reach USD 3.63 billion by 2030 from USD 2.58 billion in 2024, growing at a CAGR of 5.9% during the forecast period 2024-2030. In all the ...
Seeking Alpha on MSN14h
Henry Schein extends gain on report of activist stake, push for board changesHenry Schein (NASDAQ:HSIC) rose 7.4% amid a report that an activist investor has taken a stake and is pushing for the dental ...
Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.5, a high estimate of $82.00, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback